Control of gp130 expression by the mitogen-activated protein kinase ERK2

Oncogene

Volumn 33, Issue 17, 2014, Pages 2255-2263

  Bonito, N A ^a   Drechsler, J ^b   Stoecker, S ^a   Carmo, C R ^a,c   Seckl, M J ^a   Hermanns, H M ^a   Costa Pereira, A P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

ERK; gp130; IL 6 type cytokines; JAK STAT signalling; receptor expression

Indexed keywords

DACTINOMYCIN; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT1 PROTEIN; STAT3 PROTEIN;

ARTICLE; BINDING AFFINITY; BREAST CANCER CELL LINE; CERVICAL CANCER CELL LINE; DOWN REGULATION; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE INDUCTION; GLYCOPROTEIN GP 130 GENE; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; LUNG CANCER CELL LINE; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION;

BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84899630089     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.159     Document Type: Article

References (53)

1. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011; 70(Suppl 1): i104-i108.
2. Yamanaka Y, Nakajima K, Fukada T, Hibi M, Hirano T. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J 1996; 15: 1557-1565.
3. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011; 22: 83-89.
4. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.
5. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15: 79-80.
6. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
7. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003; 22: 4150-4165.
8. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905-1913.
9. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010; 24: 1731-1745.
10. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009; 324: 1713-1716.
11. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 2005; 4: 1131-1133.
12. Schlessinger K, Levy DE. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 2005; 65: 5828-5834.
13. Santos CI, Costa-Pereira AP. Signal transducers and activators of transcription- from cytokine signalling to cancer biology. Biochim Biophys Acta 2011; 1816: 38-49.
14. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20.
15. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
16. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
17. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003; 149: 1-38.
18. Costa-Pereira AP, Bonito NA, Seckl MJ. Dysregulation of Janus kinases and signal transducers and activators of transcription in cancer. Am J Cancer Res 2011; 1: 806-816.
19. Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 2004; 20: 23-32.
20. Hermanns HM, Radtke S, Schaper F, Heinrich PC, Behrmann I. Non-redundant signal transduction of interleukin-6-type cytokines. The adapter protein Shc is specifically recruited to rhe oncostatin M receptor. J Biol Chem 2000; 275: 40742-40748.
21. Schiemann WP, Bartoe JL, Nathanson NM. Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogen-activated protein kinase. Evidence for participation of multiple signaling pathways which converge at Ras. J Biol Chem 1997; 272: 16631-16636.
22. Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y, Yamaguchi T et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996; 5: 449-460.
23. Stuhlmann-Laeisz C, Lang S, Chalaris A, Krzysztof P, Enge S, Eichler J et al. Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol Biol Cell 2006; 17: 2986-2995.
24. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457: 200-204.
25. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 2006; 97: 439-447.
26. Hirai H, Karian P, Kikyo N. Regulation of embryonic stem cell self-renewal and pluripotency by leukaemia inhibitory factor. Biochem J 2011; 438: 11-23.
27. Lefloch R, Pouyssegur J, Lenormand P. Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol 2008; 28: 511-527.
28. Saba-El-Leil MK, Vella FD, Vernay B, Voisin L, Chen L, Labrecque N et al. An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO reports 2003; 4: 964-968.
29. Pages G, Guerin S, Grall D, Bonino F, Smith A, Anjuere F et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999; 286: 1374-1377.
30. Bourcier C, Jacquel A, Hess J, Peyrottes I, Angel P, Hofman P et al. p44 mitogenactivated protein kinase (extracellular signal-regulated kinase 1)-dependent signaling contributes to epithelial skin carcinogenesis. Cancer Res 2006; 66: 2700-2707.
31. Rodriguez J, Crespo P. Working without kinase activity: phosphotransfer-independent functions of extracellular signal-regulated kinases. Sci Signal 2011; 4: re3.
32. Voisin L, Saba-El-Leil MK, Julien C, Fremin C, Meloche S. Genetic demonstration of a redundant role of extracellular signal-regulated kinase 1 (ERK1) and ERK2 mitogen-activated protein kinases in promoting fibroblast proliferation. Mol Cell Biol 2010; 30: 2918-2932.
33. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 320-344.
34. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 2009; 8: 1168-1175.
35. Pouyssegur J, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Eur J Biochem 2003; 270: 3291-3299.
36. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B et al. MAP kinases. Chem Rev 2001; 101: 2449-2476.
37. Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, Brambilla R. ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol 2006; 5: 14.
38. Lavagni P, Indrigo M, Colombo G, Martegani E, Rosenblum K, Gnesutta N et al. Identification of novel RasGRF1 interacting partners by large-scale proteomic analysis. J Mol Neurosci 2009; 37: 212-224.
39. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 2010; 38: 114-127.
40. Krens SF, Corredor-Adamez M, He S, Snaar-Jagalska BE, Spaink HP. ERK1 and ERK2 MAPK are key regulators of distinct gene sets in zebrafish embryogenesis. BMC Genomics 2008; 9: 196.
41. Marchi M, D'Antoni A, Formentini I, Parra R, Brambilla R, Ratto GM et al. The N-terminal domain of ERK1 accounts for the functional differences with ERK2. PLoS One 2008; 3: e3873.
42. Hu S, Xie Z, Onishi A, Yu X, Jiang L, Lin J et al. Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell 2009; 139: 610-622.
43. Cohen-Armon M, Visochek L, Rozensal D, Kalal A, Geistrikh I, Klein R et al. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell 2007; 25: 297-308.
44. Shapiro PS, Whalen AM, Tolwinski NS, Wilsbacher J, Froelich-Ammon SJ, Garcia M et al. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol 1999; 19: 3551-3560.
45. Roy SK, Hu J, Meng Q, Xia Y, Shapiro PS, Reddy SP et al. MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc Natl Acad Sci USA 2002; 99: 7945-7950.
46. O'Brien CA, Manolagas SC. Isolation and characterization of the human gp130 promoter. Regulation by STATS. J Biol Chem 1997; 272: 15003-15010.
47. Jain N, Zhang T, Fong SL, Lim CP, Cao X. Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene 1998; 17: 3157-3167.
48. Pokholok DK, Zeitlinger J, Hannett NM, Reynolds DB, Young RA. Activated signal transduction kinases frequently occupy target genes. Science 2006; 313: 533-536.
49. Fasnacht N, Muller W. Conditional gp130 deficient mouse mutants. Semin Cell Dev Biol 2008; 19: 379-384.
50. Radtke S, Wuller S, Yang XP, Lippok BE, Mutze B, Mais C et al. Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation. J Cell Sci 2010; 123: 947-959.
51. Marchetti A, Cecchinelli B, D'Angelo M, D'Orazi G, Crescenzi M, Sacchi A et al. p53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. Cell Death Differ 2004; 11: 596-607.
52. Watling D, Carmo CR, Kerr IM, Costa-Pereira AP. Multiple kinases in the interferon-gamma response. Proc Natl Acad Sci USA 2008; 105: 6051-6056.
53. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.